Teva Pharmaceutical Industries (TEVA) Revenue & Revenue Breakdown
Teva Pharmaceutical Industries Revenue Highlights
Latest Revenue (Y)
$16.54B
Latest Revenue (Q)
$4.18B
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
Teva Pharmaceutical Industries Revenue by Period
Teva Pharmaceutical Industries Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $16.54B | 4.40% |
| 2023-12-31 | $15.85B | 6.17% |
| 2022-12-31 | $14.93B | -6.00% |
| 2021-12-31 | $15.88B | -4.68% |
| 2020-12-31 | $16.66B | -1.36% |
| 2019-12-31 | $16.89B | -10.43% |
| 2018-12-31 | $18.85B | -15.77% |
| 2017-12-31 | $22.39B | 2.20% |
| 2016-12-31 | $21.90B | 11.45% |
| 2015-12-31 | $19.65B | -3.06% |
| 2014-12-31 | $20.27B | -0.21% |
| 2013-12-31 | $20.31B | -0.01% |
| 2012-12-31 | $20.32B | 10.95% |
| 2011-12-31 | $18.31B | 13.59% |
| 2010-12-31 | $16.12B | 15.99% |
| 2009-12-31 | $13.90B | 25.39% |
| 2008-12-31 | $11.09B | 17.83% |
| 2007-12-31 | $9.41B | 11.89% |
| 2006-12-31 | $8.41B | 60.14% |
| 2005-12-31 | $5.25B | 9.41% |
| 2004-12-31 | $4.80B | 46.47% |
| 2003-12-31 | $3.28B | 30.09% |
| 2002-12-31 | $2.52B | 21.24% |
| 2001-12-31 | $2.08B | 18.72% |
| 2000-12-31 | $1.75B | 36.45% |
| 1999-12-31 | $1.28B | 14.92% |
| 1998-12-31 | $1.12B | -0.09% |
| 1997-12-31 | $1.12B | 17.10% |
| 1996-12-31 | $953.80M | 42.85% |
| 1995-12-31 | $667.70M | 13.61% |
| 1994-12-31 | $587.70M | 17.07% |
| 1993-12-31 | $502.00M | - |
Teva Pharmaceutical Industries generated $16.54B in revenue during NA 2024, up 4.40% compared to the previous quarter, and up 97.97% compared to the same period a year ago.
Teva Pharmaceutical Industries Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | $4.18B | 7.32% |
| 2025-03-31 | $3.89B | -7.99% |
| 2024-12-31 | $4.23B | -2.38% |
| 2024-09-30 | $4.33B | 4.08% |
| 2024-06-30 | $4.16B | 8.61% |
| 2024-03-31 | $3.83B | -14.02% |
| 2023-12-31 | $4.46B | 15.77% |
| 2023-09-30 | $3.85B | -0.72% |
| 2023-06-30 | $3.88B | 5.90% |
| 2023-03-31 | $3.66B | -5.72% |
| 2022-12-31 | $3.88B | 8.04% |
| 2022-09-30 | $3.60B | -5.02% |
| 2022-06-30 | $3.79B | 3.39% |
| 2022-03-31 | $3.66B | -10.71% |
| 2021-12-31 | $4.10B | 5.51% |
| 2021-09-30 | $3.89B | -0.61% |
| 2021-06-30 | $3.91B | -1.81% |
| 2021-03-31 | $3.98B | -10.56% |
| 2020-12-31 | $4.45B | 11.92% |
| 2020-09-30 | $3.98B | 2.79% |
| 2020-06-30 | $3.87B | -11.18% |
| 2020-03-31 | $4.36B | -2.48% |
| 2019-12-31 | $4.47B | 4.78% |
| 2019-09-30 | $4.26B | -1.68% |
| 2019-06-30 | $4.34B | 0.98% |
| 2019-03-31 | $4.29B | -5.79% |
| 2018-12-31 | $4.56B | 0.66% |
| 2018-09-30 | $4.53B | -3.66% |
| 2018-06-30 | $4.70B | -7.19% |
| 2018-03-31 | $5.07B | -7.22% |
| 2017-12-31 | $5.46B | -2.69% |
| 2017-09-30 | $5.61B | -1.34% |
| 2017-06-30 | $5.69B | 0.99% |
| 2017-03-31 | $5.63B | -13.28% |
| 2016-12-31 | $6.49B | 16.70% |
| 2016-09-30 | $5.56B | 10.42% |
| 2016-06-30 | $5.04B | 4.74% |
| 2016-03-31 | $4.81B | -1.45% |
| 2015-12-31 | $4.88B | 1.20% |
| 2015-09-30 | $4.82B | -2.88% |
| 2015-06-30 | $4.97B | -0.32% |
| 2015-03-31 | $4.98B | -3.60% |
| 2014-12-31 | $5.17B | 2.17% |
| 2014-09-30 | $5.06B | 0.26% |
| 2014-06-30 | $5.04B | 0.88% |
| 2014-03-31 | $5.00B | -7.90% |
| 2013-12-31 | $5.43B | 7.33% |
| 2013-09-30 | $5.06B | 2.74% |
| 2013-06-30 | $4.92B | 0.47% |
| 2013-03-31 | $4.90B | -6.63% |
| 2012-12-31 | $5.25B | 5.57% |
| 2012-09-30 | $4.97B | -0.44% |
| 2012-06-30 | $4.99B | -2.12% |
| 2012-03-31 | $5.10B | -10.11% |
| 2011-12-31 | $5.68B | 30.66% |
| 2011-09-30 | $4.34B | 3.13% |
| 2011-06-30 | $4.21B | 3.24% |
| 2011-03-31 | $4.08B | -7.65% |
| 2010-12-31 | $4.42B | 3.95% |
| 2010-09-30 | $4.25B | 11.84% |
| 2010-06-30 | $3.80B | 4.02% |
| 2010-03-31 | $3.65B | -3.92% |
| 2009-12-31 | $3.80B | 7.10% |
| 2009-09-30 | $3.55B | 4.41% |
| 2009-06-30 | $3.40B | 8.04% |
| 2009-03-31 | $3.15B | 10.50% |
| 2008-12-31 | $2.85B | 0.21% |
| 2008-09-30 | $2.84B | 0.67% |
| 2008-06-30 | $2.82B | 9.76% |
| 2008-03-31 | $2.57B | - |
Teva Pharmaceutical Industries generated $4.18B in revenue during Q2 2025, up 7.32% compared to the previous quarter, and up 108.98% compared to the same period a year ago.
Teva Pharmaceutical Industries Revenue Breakdown
Teva Pharmaceutical Industries Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| Distribution Service | $1.58B | - | - | - | - |
| Product | $14.43B | - | - | - | - |
| Product and Service, Other | $365.00M | - | - | - | - |
| License | $173.00M | - | - | - | - |
| Other Activities | - | $926.00M | $1.04B | $1.15B | $1.30B |
| International Markets | - | $1.96B | $1.90B | $2.03B | $2.15B |
Teva Pharmaceutical Industries's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product (87.22%), Distribution Service (9.53%), Product and Service, Other (2.21%), and License (1.05%).
Quarterly Revenue by Product
| Product/Service | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product and Service, Other | $117.00M | $76.00M | $157.00M | $102.00M | $106.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Distribution Service | $377.00M | $384.00M | $804.00M | $390.00M | $382.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Product | $3.64B | $3.40B | $7.00B | $3.79B | $3.64B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| License | $46.00M | $36.00M | $92.00M | $45.00M | $36.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Activities | - | - | - | - | - | $462.00M | $245.00M | $219.00M | $272.00M | $241.00M | $257.00M | $275.00M | $302.00M | $262.00M | $298.00M | $289.00M | $345.00M | $316.00M | $335.00M | $307.00M |
| International Markets | - | - | - | - | - | $987.00M | $479.00M | $492.00M | $481.00M | $475.00M | $454.00M | $492.00M | $527.00M | $530.00M | $485.00M | $490.00M | $572.00M | $529.00M | $488.00M | $565.00M |
Teva Pharmaceutical Industries's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Product (87.07%), Distribution Service (9.03%), Product and Service, Other (2.80%), and License (1.10%).
Teva Pharmaceutical Industries Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| UNITED STATES | $8.03B | - | - | - | - |
| Europe | $5.10B | $4.84B | $4.46B | $4.81B | $4.74B |
| North America | - | $8.12B | $5.83B | $6.39B | $6.90B |
Teva Pharmaceutical Industries's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (61.16%), and Europe (38.84%).
Quarterly Revenue by Country
| Country | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Europe Segment | $1.30B | $1.19B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| United States Segment | $2.15B | $1.91B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| International Markets | $495.00M | $582.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| UNITED STATES | - | $1.91B | $3.70B | $2.23B | $2.11B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| North America Segment | - | $1.91B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Europe | - | $1.20B | $2.63B | $1.26B | $1.21B | $2.51B | $1.15B | $1.18B | $1.16B | $1.03B | $1.13B | $1.13B | $1.25B | $1.20B | $1.19B | $1.18B | $1.25B | $7.00M | $1.00B | $1.37B |
| North America | - | - | - | - | - | $5.23B | $1.58B | $1.32B | $1.53B | $1.39B | $1.54B | $1.38B | $1.62B | $1.49B | $1.62B | $1.67B | $1.96B | $1.66B | $1.66B | $1.63B |
Teva Pharmaceutical Industries's latest quarterly revenue breakdown by geography, as of Jun 25: United States Segment (54.54%), Europe Segment (32.91%), and International Markets (12.55%).
Teva Pharmaceutical Industries Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| TEVA | Teva Pharmaceutical Industries | $16.54B | $4.18B |
| GMAB | Genmab | $16.47B | $4.14B |
| LH | Labcorp | $12.16B | $3.53B |
| DGX | Quest Diagnostics | $9.87B | $2.82B |
| BIIB | Biogen | $9.68B | $2.65B |
| STE | STERIS | $5.46B | $1.39B |
| BNTX | BioNTech SE | $3.82B | $187.60M |
| WAT | Waters | $2.96B | $771.33M |
| NBIX | Neurocrine Biosciences | $2.36B | $687.50M |
| PODD | Insulet | $2.07B | $649.10M |
| NTRA | Natera | $1.70B | $501.83M |